Israel's IceCure Medical said on Sunday it has received U.S. regulatory approval to expand the use of its cryoablation technology to treat benign and cancerous tumors in livers and kidneys, sending its share price up 30%.
IceCure's treatment uses special needles to inject liquid nitrogen to freeze and destroy tumors without the need for surgery.

